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ABSTRACT 
Epigenetic changes represent a potential mechanism underlying associations of early-life exposures and 
later-life health outcomes. Population-based cohort studies starting in early life are an attractive 
framework to study the role of such changes. DNA methylation is the most studied epigenetic mechanism 
in population research. We discuss the application of DNA methylation in early-life population studies, 
some recent findings, key challenges and recommendations for future research. Studies into DNA 
methylation within the DOHaD framework generally either explore associations between prenatal 
exposures and offspring DNA methylation or associations between offspring DNA methylation in early 
life and later health outcomes. Only few studies to date have integrated prospective exposure, epigenetic 
and phenotypic data in order to explicitly test the role of DNA methylation as a potential biological 
mediator of environmental effects on health outcomes. Population epigenetics is an emerging field which 
has challenges in terms of methodology and interpretation of the data. Key challenges include tissue 
specificity, cell type adjustment, issues of power and comparability of findings, genetic influences, and 
exploring causality and functional consequences. Ongoing studies are working on addressing these issues. 
Large collaborative efforts of prospective cohorts are emerging, with clear benefits in terms of optimizing 
power and use of resources, and in advancing methodology. In the future, multidisciplinary approaches, 
within and beyond longitudinal birth and preconception cohorts will advance this complex, but highly 
promising, field of research. 
Keywords: Epigenetics; Cohort Studies; DNA-methylation; Epidemiology, Molecular
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Introduction 
In the Developmental Origins of Health and Disease framework
1,2
, many associations between the early-
life environment (e.g. prenatal exposure to maternal obesity, smoking and suboptimal diet) and later 
health outcomes have been described
3-6
. However, the underlying molecular mechanisms are often not 
known. Epigenetic changes have recently emerged as a potential mechanism that may at least partially 
explain these associations.  
What is epigenetics 
The ‘epigenome’ refers to a collection of molecular mechanisms, which do not affect the DNA sequence, 
but can affect gene regulation by changing the structure and accessibility of the DNA. Three main types 
of epigenetic mechanisms can be distinguished: DNA methylation, histone modifications and non-coding 
RNAs. These mechanisms are not independent, but rather function together as part of the larger, complex 
epigenetic machinery
7
. Here, we focus specifically on DNA methylation, as this is currently the most 
studied epigenetic mark in large population studies. DNA methylation refers to the binding of a methyl 
group to the DNA, mainly at positions where a cytosine is located next to a guanine, a cytosine-
phosphate-guanine (CpG) site
8
. Typically (but not always), higher levels of DNA methylation at CpG 
sites in promoter or enhancer regions of a gene impede transcription factors from binding to the DNA, 
thereby inhibiting gene expression. On the contrary, methylation of CpG sites in a gene body generally 
leads to increased expression
8
. Because DNA methylation patterns can be passed on mitotically during 
cell division, they can lead to long-term alterations in gene activity and related phenotypes
9
. At the same 
time, DNA methylation patterns can also show a considerable degree of flexibility over time, enabling 
cells to respond to changing internal and external inputs. 
DNA methylation within the DOHaD framework 
Interest in DNA methylation within the DOHaD framework stems from the fact that (a) it has been shown 
to respond to both genetic and environmental influences, beginning in utero, and (b) it plays a 
fundamental role in development
10,11
. Consequently, DNA methylation shows promise as a mechanism 
for understanding how environmental and genetic influences shape trajectories of health and disease 
across the lifespan.  
Early life, in particular, may be a critical period for epigenetic effects on health outcomes. 
Extensive reprogramming of DNA methylation patterns takes place in utero
12
. Thus, aberrant 
modifications that occur at this early stage, before tissue differentiation, could result in alterations in gene 
expression across many tissue types. In addition, environmental and genetic effects on organ maturation 
during critical periods in pregnancy and postnatally may be mediated through the epigenome. Evidence 
for this has come primarily from animal experimental studies, which enable careful manipulation of 
environmental exposures
13
. In humans, an early example is the work performed in the Dutch Famine 
Study, which has shown that exposure to famine in the first trimester of pregnancy, but not the last, is 
associated with DNA methylation changes at the imprinted IGF2 gene, a key modulator of fetal 
development
14
. Timing-specific effects were later found for further loci, some of which also associated 
with cardiometabolic phenotypes, such as birth weight and LDL cholesterol levels
15,16
. Together, this 
work provided preliminary evidence that (very) early life may be a critical period for epigenetically-
mediated effects of environmental exposures on health outcomes. Also, twin studies have been 
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instrumental in disentangling the relative contributions of genetic, environmental and stochastic factors to 
DNA methylation and phenotypic variability
11,17
. 
Population-based cohort studies starting in early life offer an attractive platform to build on this 
early work  and characterize associations between early-life exposures, epigenetic mechanisms and later-
life health. Below, we discuss the application of DNA methylation in early-life population research, 
including some recent findings, key challenges and recommendations for future research.  
 
DNA methylation in early-life population-based cohort studies 
In population-based studies, there is increasing interest in the role of DNA methylation changes in 
observational associations of adverse exposures in the preconception period, during pregnancy and in 
early infancy with later-life common diseases. Through the development of high-throughput cost-
effective arrays which analyze hundreds of thousands of DNA methylation markers across the genome, it 
has become possible to measure DNA methylation in (relatively) large samples. Levels of DNA 
methylation at these markers are then associated with determinants and outcomes of health and disease in 
“epigenome-wide association studies” or EWASs. In addition, many long-running population-based 
studies have longitudinal collection of data and biological samples in extensive biobanks. This makes it 
possible to study DNA methylation over time in relation to repeated measurements of exposures and 
outcomes and to test key mediational hypotheses.  
So far, population-based research examining epigenetics within the DOHaD framework has fallen 
mainly into two categories – (i) studies investigating associations between prenatal exposures and 
offspring DNA methylation patterns, e.g. dietary, environmental, and psychosocial exposures (Fig 1a: a 
path); and (ii) studies investigating associations between offspring DNA methylation patterns in early life 
and later health outcomes, e.g. neurodevelopment or cardiometabolic health (Fig 1a: b path). In both 
cases, DNA methylation has typically been examined at birth, either in cord blood or in placental tissue, 
given its role as a barrier and interface between maternal and fetal environments.  
Early-life exposures and DNA methylation 
To date, the prenatal exposure that has been most robustly linked to DNA methylation changes in the 
offspring is maternal smoking
18-23
. In a recent large study based on data from 13 cohorts (n = 6,685), 
Joubert et al found that sustained smoking during pregnancy associated with altered DNA methylation 
patterns across thousands of CpG sites, an effect that was still observable – albeit to a lesser extent – in 
older children, although the sample size was around half that of the newborn analysis
18
. This study’s top 
finding was a CpG in AHRR, which has been associated with both personal and maternal smoking in 
multiple other studies
19,24,25
. Pathway analyses found neurological and developmental pathways, which is 
in line with the maternal smoking-related child outcomes. Alterations in DNA methylation at birth have 
also been documented in relation to other chemicals, such as prenatal exposure to arsenic
26
, mercury
27
 and 
air pollution 
28,29
.  
Maternal pre-pregnancy body mass index (BMI) has also been associated with offspring DNA 
methylation, with findings showing associations with both lower and higher maternal BMI in a recent 
meta-analysis of 9340 newborns
30
. Effects were generally small, with a median increase of 0.03% in 
methylation level per unit increase in maternal BMI, and strong evidence for a direct causal intra-uterine 
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effect was lacking for most loci
30
. Furthermore, dietary factors have been examined, with a particular 
focus on folate intake, due to its established role in both epigenetic regulation and fetal brain 
development
31
. The largest of these studies, based on data from two birth-cohorts (n = 1,988), reported 
associations between maternal plasma folate levels during pregnancy and differential DNA methylation in 
cord blood across multiple genes involved in folate biology and neurodevelopmental processes
32
. 
Interestingly, this study found reduced methylation with higher levels of folate, a methyl donor, at the 
vast majority of CpG sites, a finding which underlines the complex associations of the one-carbon 
metabolism pathway with methylation
32
. In contrast, other known risk factors for poorer offspring health 
have not been found to be strongly associated with neonatal DNA methylation. For example, a recent 
meta-analysis on maternal alcohol use found no evidence for an association with cord blood DNA 
methylation
33
. 
33
 Similarly, a meta-analysis of prenatal maternal stress did not identify associations with 
DNA methylation in cord blood, although an enrichment for genes related to methyltransferase activity 
was identified
34
. Besides a true null effect, the lack of a strong signal in these studies may reflect low 
levels of more severe forms of exposure in the general population, relatively small sample sizes, resulting 
in decreased power to detect effects, or heterogeneity between the included studies in terms of population, 
exposure definition or confounding structure.  
DNA methylation and childhood health outcomes 
Compared to prenatal exposures, fewer population-based studies have examined the relationship between 
DNA methylation patterns and childhood health outcomes. We highlight here two important areas of 
progress in the field of DNA methylation in population-based studies: neurodevelopment and adiposity. 
For neurodevelopmental outcomes, most of the evidence to date on this topic has been drawn 
from cross-sectional data in smaller, selected samples, e.g. high-risk/clinical samples, although efforts to 
characterize these associations in the wider population are fast increasing. One such study, based on data 
from 537 newborns, found that epigenetic patterning of glucocorticoid genes in the placenta prospectively 
associated with infant neurodevelopmental profiles
35
. Specifically, infant membership to a reactive, 
poorly regulated profile associated with increased placental methylation of the NR3C1glucocorticoid 
receptor gene, and decreased methylation of the HSD11B2 gene involved in limiting fetal exposure to 
maternal circulating cortisol. Other population studies have examined DNA methylation in relation to risk 
for neurodevelopmental disorders – particularly ADHD, but also other psychiatric problems with early 
developmental origins, such as oppositional defiant and conduct problem behavior
36-39
.  For example, a 
longitudinal epigenome-wide study based on over 800 children found that DNA methylation patterns at 
birth (but not at age 7) prospectively associated with trajectories of ADHD symptoms from childhood to 
adolescence
39
. Of the 13 genome-wide significant loci identified at birth, several were annotated to genes 
involved in fatty acid metabolism and neural tube development. Importantly, one of the loci was 
annotated to a gene (ST4GAL3) that has been recently identified as the top genetic hit for ADHD in the 
largest GWAS to date. Studies are also beginning to integrate brain imaging data to investigate the links 
between DNA methylation, brain development and neuropsychiatric outcomes. For example, a recent 
EWAS study found that SP6 methylation at birth prospectively associated with lower amygdala-
hippocampal volume and higher psychotic symptoms in young adulthood – an association that was 
replicated in an independent sample of patients with schizophrenia
40
.  
 Most of the evidence regarding DNA methylation and adiposity stems from adult studies
41-46
. The 
largest of these identified and replicated cross-sectional associations between DNA methylation at 187 
loci and BMI in over 10,000 samples, showing that these are mostly a consequence rather than a cause of 
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adiposity
46
. Less is known about DNA methylation and childhood adiposity. Several studies have 
described associations of DNA methylation with birth weight, with a limited number of CpG sites 
identified in more than one study
47-51
. No strong evidence was found for persistence of associations into 
later life in the two studies that explored longitudinal relationships
47,51
. In targeted analyses, a replicable 
association of RXRA methylation in umbilical cord tissue with childhood fat mass was shown
52
. Several 
differentially methylated regions in newborn blood, such as the promoter of the long non-coding RNA 
ANRIL, have been associated with childhood adiposity measures based on epigenome-wide scans
53,54
. In 
cross-sectional analyses in children and adolescents, DNA methylation in several regions has been 
associated with adiposity measures, including the SOCS3 locus
55-57
. It remains unclear whether DNA 
methylation patterns are a risk factor for or consequence of adiposity. Detailed associations in the large 
adult EWAS show that changes in DNA methylation are mostly a consequence of obesity
46
. This is 
supported by smaller studies in children and individuals before and after bariatric surgery
58-61
. 
DNA methylation as a mediator  
Despite promising findings, very few population-based studies to date have integrated prospective 
exposure, epigenetic and phenotypic data in order to explicitly test the role of DNA methylation as a 
potential biological mediator of environmental effects on health outcomes. Notable exceptions include an 
EWAS study based on 321 cord blood samples, which showed that, in males, DNA methylation of the 
PON1 gene at birth associated with prenatal mercury levels and predicted cognitive performance scores 
during childhood
27
. Using repeated measures of DNA methylation, the authors found that this effect 
persisted in early childhood (3-5 years) and was attenuated in mid-childhood (6-10 years). Furthermore, 
DNA methylation of the PON1 locus at birth was shown to associate with gene expression levels in an 
independent set of cord blood samples. Another exception is a longitudinal EWAS study examining 
epigenetic correlates of adolescent substance use (tobacco, alcohol and 
cannabis use; n = 244; age 14–18). This study found that neonatal DNA methylation levels in a tightly 
interconnected network of genes enriched for neurodevelopmental processes (n = 65 epigenome-wide 
corrected loci) partially mediated the effect of prenatal tobacco smoking on later substance use risk in 
adolescence
62
. Relatedly, maternal prenatal smoking has been found by other studies to associate with 
lower birth weight partially through alterations in cord blood DNA methylation using both targeted and 
epigenome-wide approaches
24,63
.  
 
Current challenges and future directions 
The field of population epigenetics is still in its infancy. Although great strides have already been taken, 
there is still much to discover and learn. Here we present some of the key challenges that current research 
in this area is facing, and how these may be addressed.  
Tissue specificity 
DNA methylation patterns are largely tissue-specific. In large cohort studies, blood is typically the main 
source of DNA collected. In some cases there may be DNA from buccal swabs, umbilical cord or 
placental tissue, but other tissues are generally inaccessible for population researchers. This poses 
challenges, as the extent to which findings may be generalized to the target tissue of interest is often 
unclear
64,65
. One way to address this limitation is to refer to publicly available datasets that show cross-
tissue concordance in DNA methylation patterns, based on selected samples (e.g. comparison of blood 
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and brain in postmortem samples or blood and adipose tissue in patients undergoing surgery), for 
example: http://epigenetics.iop.kcl.ac.uk/bloodbrain, and https://redgar598.shinyapps.io/BECon/ 
66-68
. 
However, it is not just the concordance in DNA methylation levels between tissues, but also, and maybe 
more so, the variability of those DNA methylation levels in association with the exposure or outcome of 
interest that matters. Concordance between tissues in associations with specific phenotypes has been 
shown, for example for BMI between blood, adipose and liver tissue, but overall evidence is limited 
46,64,69
. The NIH Roadmap Epigenomics Project can be used as a reference for epigenetic marks in a large 
number of tissues (www.roadmapepigenomics.org)
70
.  
Cell type adjustment 
DNA methylation patterns vary not only between, but also within tissues. In blood samples, DNA is 
collected from leukocytes, which represent a heterogeneous population characterized by cell-type specific 
DNA methylation. As such, the relative proportions of cell types from which the DNA is extracted may 
influence epigenetic results. Ideally, detailed measurements of leukocyte subtypes would be available for 
correction in all study participants, but this is often not feasible. As an alternative, the use of reference-
based approaches for estimating cell type proportions has become popular, such as methods developed for 
whole blood
71,72
 and, more recently, cord blood
73-75
. Reference-free methods are also available
76-78
 . These 
methods, however, are still under development and population-based studies with specific cell type 
measurements can play a pivotal role in developing and validating new analytic approaches.  
Methodological considerations 
DNA methylation data are multifactorial, high dimensional and inter-correlated, raising questions about 
how best they should be analyzed
79
. So far, studies have varied widely in study characteristics, 
methodology and analytic routines, limiting comparability of findings. Furthermore, many studies have 
been underpowered to identify effects, especially when examining exposures or outcomes with low 
prevalence in the general population. To address these challenges, large collaborative efforts of 
prospective cohorts, such as the Pregnancy And Childhood Epigenetics (PACE) Consortium, have 
emerged, similar to the field of genome-wide association studies although numbers are still much 
smaller
80
. Such collaborations have shown enormous potential in increasing statistical power and 
optimizing the use of resources
81-85
, as well as allowing replication and comparison of effects between 
studies with potentially heterogeneous confounding structures, thus strengthening the evidence for 
reported associations. In addition, they are a valuable platform for standardization of study design and 
analysis protocols to maximize comparability and help to delineate best practices in the field. 
Multidisciplinary teams, bringing together basic, population and clinical scientists, will enable easier 
exchange of knowledge and ideas, translation between bench, population and bedside, and strengthening 
of scientific conclusions by bringing together multiple lines of evidence. 
Role of genetics 
It has been reported that a substantial proportion of the variation in DNA methylation between individuals 
is due to genetic variants, acting in cis or trans (mQTLs)
86-88
.  As such, measured DNA methylation levels 
may reflect genotype and mediate associations of genetic variants and health outcomes, or, if genotype 
drives both DNA methylation and the outcome under study, changes in DNA methylation may be an 
epiphenomenon of the genetic risk rather than part of the causal pathway. Furthermore, genetic factors 
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may moderate associations between environmental exposures, DNA methylation and outcomes (Fig1a). 
Thus, genetic variability should always be considered when examining DNA methylation – ideally 
directly, or if unavailable or underpowered, by referring to online mQTL databases (e.g. 
www.mqtldb.org
87
). 
Causal inference  
DNA methylation is a dynamic process that may change under the influence of genetic and environmental 
factors, but also with disease states. Thus, DNA methylation may be a cause, a consequence, or an 
epiphenomenon of the phenotype under study (Fig1b). This issue of reverse causality is particularly 
problematic when using cross-sectional designs. While the use of prospective, longitudinal data partially 
addresses directionality  -  especially when DNA methylation is measured before the onset of disease - 
observational studies in general are subject to confounding. The application of advanced causal inference 
methods, such as two-step Mendelian randomization offers a valuable tool for probing causal pathways
89
. 
For example, a recent study applied this method to support a small, causal effect of prenatal maternal B12 
levels on childhood IQ levels, via DNA methylation at birth
90
. The tissue specificity of DNA methylation 
is an additional challenge to causal inference analyses. 
Determining whether DNA methylation plays a causal role in disease is important  for 
understanding the etiology of the disease as well as potentially developing new therapies in future. Yet, 
even  if DNA methylation changes are not causal to a disease, but rather a consequence or an 
epiphenomenon, they may still serve as biomarkers of the disease or its progression (Fig1b)
91
. In addition, 
if an association of DNA methylation with a phenotype is non-causal, the DNA methylation level may be 
used as a proxy for a specific exposure. This may be especially helpful for exposures that are difficult to 
measure (reliably). Previous studies have shown the potential of using DNA methylation as a biomarker 
in a number of these instances, including for alcohol consumption, maternal smoking during pregnancy 
and gestational age
92-95
. 
Functional characterization  
The buck does not stop at DNA methylation. To understand pathways leading to disease, we need to 
study the functional effects in terms of gene expression as well as the roles of other epigenetic marks. 
Effect sizes in EWAS are often small, for example in an EWAS of maternal BMI, the largest effect 
estimates for the significantly associated CpG sites were an 0.1% decrease or increase in methylation 
level per unit increase in maternal BMI (kg/m
2
)
30
. For a strong exposure such as sustained maternal 
smoking, the maximum effect size was a 10% decrease in methylation levels for sustained smokers 
compared to non-smokers
18
. It is currently unclear to what extent statistical significance parallels 
biological meaningfulness. In future, studies that incorporate both DNA methylation and expression data, 
preferably within the same population and at the same time point, can shed more light on this question of 
functionality. Such data are not widely available in longitudinal birth cohorts yet, with some noticeable 
exceptions (INMA Study, Gambia Study)
96,97
. In addition, the ENCODE database can be used to explore 
whether identified DNA methylation sites are located in potential regulatory regions
36
. Intensifying 
collaborations and expanding them to researchers in neighboring fields, such as clinical and basic 
researchers, will make it easier to build chains of evidence across species, across research fields and 
across the life course, leading to strong and innovative research.  
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Starting at the very beginning 
Most early-life cohorts begin in pregnancy and thus generally do not have prospective and hands-on data 
about the preconception and early pregnancy periods. Some preconception cohorts do exist (Southampton 
Women’s Survey: www.mrc.soton.ac.uk/sws98 , Generation R Next Study: www.generationr.nl/next) and 
they, together with longitudinal birth cohorts with follow-up long enough to include the next generation, 
will provide valuable information on exposures in these very early life stages and their epigenetic 
associations. Furthermore, the vast majority of epigenetic research in birth cohorts is currently focused on 
maternal exposures during pregnancy. In contrast, the contribution of paternal epigenetics and exposures 
is currently understudied, but has the potential to lend important new insights in the development of the 
offspring epigenome and the pathways leading from early life exposures to child and adolescent health. 
 
Conclusion 
Population epigenetics is an emerging field with strong potential to shed light on mechanisms underlying 
associations of early-life adverse exposures and later life health. Yet, the field is still under development 
and poses challenges in terms of methodology and interpretation of the data. The use of multidisciplinary 
approaches, combining various “omics” studies linking epigenetic changes to functional readouts and 
phenotypes, within and beyond longitudinal birth and preconception cohorts are needed to advance the 
field and shed further light on this complex, but highly promising, field of research. 
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Figure 1  
 
a. The causal mediation model, whereby prenatal exposures (independent variable) partly influence health 
outcomes in the offspring (dependent variable) via changes in DNA methylation (mediator variable). Of 
note, both the a path and the b path are hypothesised to be moderated by genetic effects, as well as 
additional factors. Furthermore, DNA methylation may also mediate genetic (as well as environmental) 
effects. b. The alternative non-causal model, whereby DNA methylation can serve as a biomarker of, but 
not causal mechanism in, exposure-outcome associations. Note that we present here the two models that 
are most relevant to the DOHaD framework; however, it is important to note that other models have also 
been proposed. For example, DNA methylation may function as a moderator of genetic and 
environmental influences on outcomes or as a mediator of genetic influences on outcomes. Also, 
stochastic changes may influence DNA methylation. More complex models are also possible [see for a 
more detailed discussion:
91
]. 
 
